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Introduction
Due to its reduced density, Helium/Oxygen (He/O2)
reduces the work of breathing, intrinsic PEEP and hyper-
capnia more than Air/O2 during non-invasive ventilation
(NIV) in COPD exacerbations [1,2]. Two prospective,
randomized multicenter trials were inconclusive in show-
ing a benefit of He/O2 NIV on outcome (intubation,
mortality, length of stay (LOS) in ICU) but were poten-
tially underpowered [3,4].
Objectives
To evaluate whether 72-hr continuous He/O2 during
both spontaneous breathing and NIV is superior to Air/
O2 in reducing NIV failure (intubation or mortality dur-
ing ICU stay) in severe hypercapnic COPD exacerba-
tions. Secondary outcomes included physiological
parameters, duration of ventilation, ICU and hospital
LOS, 6-month recurrence and rehospitalization rates.
Methods
Prospective, randomized multicenter (16 centers in
6 countries) trial, comparing the two gas mixtures for a
maximum of 72 hours. Hypothesis was that He/O2
would reduce intubation rate from 25% to 15%, resulting
in a total sample size of 670 patients. Spontaneous
breathing and NIV were applied with specific devices
for He/O2. Same ventilator was used in both arms.
Results
The trial was stopped prematurely for futility (low intu-
bation rate reported by the adjudication committee).
445 patients were included (mean ± SD 68 ± 11 yrs;
M:F 69:31%; BMI 26 ± 6 kg/m2; SAPS 3 49 ± 8; Resp
rate (RR) 29 ± 6/min - PaO2 75 ± 36 mmHg; PaCO2
69 ± 16 mmHg; pH 7.30 ± 0.06 - intention-to-treat data
set), with no baseline difference between He/O2 vs. Air/
O2. The primary outcome was negative (Figure 1) and
baseline pH was the only significant predictor of NIV
failure. NIV failure occurred in the first 72 hours (while
receiving the study treatment) in 58% of failures with
He/O2 and 84% with Air/O2 (p = 0.97). RR (Figure 2),
pH, PaCO2 and encephalopathy improved faster and
with greater magnitude with He/O2
Conclusions
NIV failure rate was not reduced by He/O2 administered
during NIV and spontaneous breathing for up to 72 hrs.
Failure rate was low in both groups, reflecting the current
efficacy of NIV in decompensated COPD. However, He/O2
led to improved physiological response, thus confirming
previous results, and a shorter duration of invasive ventila-
tion and ICU stay in patients with NIV failure.
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